FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNervGen Pharma Corp. Common stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NGEN
NervGen Pharma Corp. Common stock Stock AnalysisComprehensive stock analysis for NervGen Pharma Corp. Common stock (NGEN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNGEN
NGEN
NervGen Pharma Corp. Common stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NGEN
  1. Home
  2. Stocks
  3. NervGen Pharma Corp. Common stock
NG

NervGen Pharma Corp. Common stock

🇺🇸NGEN•NASDAQ
NG

NervGen Pharma Corp. Common stock

🇺🇸NGEN•NASDAQ
Market cap
$198.55M

Your view on NGEN

Mkt Cap
$198.55M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About NervGen Pharma Corp. Common stock

Industry
Not available
Sector
Not available
CEO
Not available
Headquarters
CA
Industry
Not available
Sector
Not available
CEO
Not available
Headquarters
CA
Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for NervGen Pharma Corp. Common stock. Starting points for NervGen Pharma Corp. Common stock: EPS -$0.65, beta 0.78. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for NervGen Pharma Corp. Common stock. Trailing twelve-month EPS for NervGen Pharma Corp. Common stock stands at -$0.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' targetCAD 12.00average of analysts' targets
Current price—

Buy

Targets, low to high

$12.00

Low $12.00

Middle $12.00

High $12.00

Analyst ratings

1 rating
  • Strong Buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−CAD 0.08−CAD 0.09−CAD 0.13−CAD 0.35
Lowest estimate−CAD 0.08−CAD 0.10−CAD 0.27−CAD 0.71
Highest estimate−CAD 0.08−CAD 0.08CAD 0.00CAD 0.00
Number of analysts2322
A year ago−CAD 0.261−CAD 0.261−CAD 0.611—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimateCAD 0.00CAD 0.00CAD 0.00CAD 0.00
Lowest estimateCAD 0.00CAD 0.00CAD 0.00CAD 0.00
Highest estimateCAD 0.00CAD 0.00CAD 0.00CAD 0.00
Number of analysts0000
A year agoCAD 0.00CAD 0.00CAD 0.00—
Growth vs a year ago————
Recent rating and target changes (2)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for NervGen Pharma Corp. Common stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NGEN2 funds
ETFs holding NervGen Pharma Corp. Common stock
TickerFundFund assets% of the fund
GWXState Street SPDR S&P International Small Cap ETF$882M in assets0.01%
IBRNiShares Neuroscience and Healthcare ETF$9M in assets0.27%

Largest holders first, then the funds most concentrated in NGEN.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold NervGen Pharma Corp. Common stock, and how their positions are changing. At a $198.6M market value, institutional positions materially move NervGen Pharma Corp. Common stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by NervGen Pharma Corp. Common stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for NervGen Pharma Corp. Common stock. Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of NervGen Pharma Corp. Common stock.

NGEN AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1